JP2011503024A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503024A5
JP2011503024A5 JP2010532555A JP2010532555A JP2011503024A5 JP 2011503024 A5 JP2011503024 A5 JP 2011503024A5 JP 2010532555 A JP2010532555 A JP 2010532555A JP 2010532555 A JP2010532555 A JP 2010532555A JP 2011503024 A5 JP2011503024 A5 JP 2011503024A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532555A
Other versions
JP2011503024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064809 external-priority patent/WO2009056631A2/en
Publication of JP2011503024A publication Critical patent/JP2011503024A/ja
Publication of JP2011503024A5 publication Critical patent/JP2011503024A5/ja
Pending legal-status Critical Current

Links

JP2010532555A 2007-11-02 2008-10-31 補体成分を調節するための分子および方法 Pending JP2011503024A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98495107P 2007-11-02 2007-11-02
PCT/EP2008/064809 WO2009056631A2 (en) 2007-11-02 2008-10-31 Molecules and methods for modulating complement component

Publications (2)

Publication Number Publication Date
JP2011503024A JP2011503024A (ja) 2011-01-27
JP2011503024A5 true JP2011503024A5 (ja) 2011-05-06

Family

ID=40343498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532555A Pending JP2011503024A (ja) 2007-11-02 2008-10-31 補体成分を調節するための分子および方法

Country Status (21)

Country Link
US (1) US20090175875A1 (ja)
EP (1) EP2207807A2 (ja)
JP (1) JP2011503024A (ja)
KR (1) KR20100067681A (ja)
CN (1) CN101848937A (ja)
AR (1) AR069130A1 (ja)
AU (1) AU2008320820A1 (ja)
CA (1) CA2703911A1 (ja)
CL (1) CL2008003241A1 (ja)
CO (1) CO6270341A2 (ja)
CR (1) CR11361A (ja)
EA (1) EA201000717A1 (ja)
IL (1) IL204722A0 (ja)
MA (1) MA31795B1 (ja)
MX (1) MX2010004833A (ja)
PE (1) PE20091388A1 (ja)
SV (1) SV2010003556A (ja)
TN (1) TN2010000169A1 (ja)
TW (1) TW200924795A (ja)
WO (1) WO2009056631A2 (ja)
ZA (1) ZA201002335B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2044111T3 (pl) 2006-06-21 2015-02-27 Musc Found For Res Dev Celowanie czynnika H dopełniacza do leczenia chorób
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
NZ584911A (en) 2007-11-02 2011-08-26 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
NZ603560A (en) 2010-05-14 2014-09-26 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
JP6110306B2 (ja) * 2010-11-29 2017-04-05 ノヴェルメッド セラピューティクス インコーポレイテッド 組織傷害を診断するための新規な抗体
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
BR122020019190B1 (pt) 2013-08-07 2023-11-21 Alexion Pharmaceuticals, Inc. Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus
CA2936346A1 (en) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein c3d and use thereof
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
EP3394089B1 (en) * 2015-12-23 2021-07-28 eleva GmbH Polypeptides for inhibiting complement activation
MA45235A (fr) 2016-06-14 2019-04-17 Regeneron Pharma Anticorps anti-c5 et leurs utilisations
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
TW202417510A (zh) * 2022-09-20 2024-05-01 美商威特拉公司 用ｃ３ｂ抗體治療補體介導之疾病及病症

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
WO1997001578A1 (en) * 1995-06-29 1997-01-16 Medical Biology Institute Method for identifying peptides that affect protein-protein interactions and complement-modulating peptides
EP1384079A2 (en) * 2001-05-02 2004-01-28 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
US7042716B2 (en) * 2003-08-25 2006-05-09 Simon John Edward Shearman Ergonomic pull-out computer housing
US20090004183A1 (en) * 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
CA2625403A1 (en) * 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
US7327547B1 (en) * 2006-01-20 2008-02-05 Epstein Barry M Circuit element and use thereof
WO2008154251A2 (en) * 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders

Similar Documents

Publication Publication Date Title
BRPI0909040A2 (ja)
BRPI0908549B8 (ja)
BRPI0918697A2 (ja)
BRPI0907698A2 (ja)
BRPI0912727A2 (ja)
BRPI0923734A2 (ja)
BRPI0908285A2 (ja)
BRPI0910485A2 (ja)
BRPI0922669A2 (ja)
BRPI0914750A2 (ja)
BRPI0908120A2 (ja)
BRPI0904541A8 (ja)
BRPI0912462A2 (ja)
BRPI0915616A2 (ja)
JP2011503024A5 (ja)
BRPI0922550A2 (ja)
BRPI0911617A2 (ja)
BRPI0909508A2 (ja)
BRPI0913605A2 (ja)
BRPI0914852A2 (ja)
CH2347250H2 (ja)
BRPI0910572A2 (ja)
BRPI0914820A2 (ja)
AR073287B1 (ja)
BRPI0923127A (ja)